Vertex gains FDA approval for expanded use of CF drug Trikafta

2023-04-27

临床3期上市批准临床结果

Vertex gains FDA approval for expanded use of CF drug Trikafta

Preview

来源: Pharmaceutical Technology

Vertex’s Trikafta is now approved to treat cystic fibrosis in children aged between two and five years with certain mutations. Credit: Jon Pauling from Pixabay.

Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) to expand the use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to treat cystic fibrosis (CF) in children aged between two and five years with certain mutations.

The treatment is now indicated for CF patients with a minimum of one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, or with a mutation in the CFTR gene that responds to Trikafta based on in vitro data.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Docetaxel Albumin Bound in Solid Tumor GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Docetaxel in Solid Tumor GlobalData

View all

It was previously approved to treat CF in children aged between six and 11 years.

Trikafta is an oral medicine and has been designed to boost the CFTR protein’s quantity and function at the cell surface.

Vertex Pharmaceuticals chief medical officer and global medicines development and medical affairs executive vice-president Carmen Bozic stated: “Since its initial approval, Trikafta has had a significant impact on the CF community, transforming the lives of thousands of people living with cystic fibrosis.

“We remain steadfast in our commitment to bringing highly effective CF treatments to people of all ages living with this disease.”

The regulatory approval for the label expansion was supported by a 24-week open-label Phase III trial conducted in 75 children with CF aged between two and five years.

The trial showcased the tolerance of Trikafta and indicated that its safety profile was in line with that observed in older age groups.

The regimen also showed improvements in sweat chloride concentration, which is a measure of CFTR function, and lung function.

Trikafta has already been approved in Switzerland, Canada, Australia, New Zealand, Israel and the US to treat CF in people aged six years and above with certain mutations.

It has also received approvals in the European Union, Iceland, Liechtenstein, Norway and the UK as KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in combination with KALYDECO (ivacaftor).

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构